Rekombinanter TNFRSF10B (Conatumumab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter TNFRSF10B (Conatumumab Biosimilar) Antikörper (ABIN7675660)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Expressionssystem
- CHO Cells
-
Verwendungszweck
- Anti-TNFRSF10B / TRAILR2 / CD262 Reference Antibody (conatumumab)
-
Sequenz
- QVQLQESGPG LVKPSQTLSL TCTVSGGSIS SGDYFWSWIR QLPGKGLEWI GHIHNSGTTY YNPSLKSRVT ISVDTSKKQF SLRLSSVTAA DTAVYYCARD RGGDYYYGMD VWGQGTTVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK,EIVLTQSPGT LSLSPGERAT LSCRASQGIS RSYLAWYQQK PGQAPSLLIY GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QFGSSPWTFG QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC
-
Produktmerkmale
- Anti-TNFRSF10B / TRAILR2 / CD262 Reference Antibody (conatumumab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 144.96 kDa.
-
Reinheit
- >95 %
-
Isotyp
- IgG1
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Kommentare
-
Therapeutic Agents by Target and Mechanism: DR5 agonist
Conditions: Cancer
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Konzentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Lagerung
- 4 °C,-80 °C
-
Informationen zur Lagerung
- +4°C,-80°C
-
-
- TNFRSF10B (Conatumumab Biosimilar)
-
Substanzklasse
- Biosimilar
-
Hintergrund
- Synonyms: TNFRSF10B (tumor necrosis factor receptor superfamily member 10B, TRAIL-R2, TRAILR2, TR-2, CD262
-
Molekulargewicht
- 144.96 kDa
-
UniProt
- O14763
Target
-